Management of children with autism spectrum disorders;Manejo de los niños con trastornos del espectro autista

Revista de Neurologia

Volumn 36, Issue 2, 2003, Pages 166-173

  Gadia, Carlos A ^a,b   Tuchman, R F ^a  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

^b Dan Marino Center   (United States)

Author keywords

Autism; Autistic spectrum disorder; Pharmacology; Psychopharmacology; Treatment

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CLOMIPRAMINE; CLONIDINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; MAGNESIUM; NALTREXONE; NEUROLEPTIC AGENT; OPIATE ANTAGONIST; PAROXETINE; PROPRANOLOL; PYRIDOXINE; RISPERIDONE; SECRETIN; SEROTONIN UPTAKE INHIBITOR;

AGGRESSION; ASPERGER SYNDROME; AUTISM; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COMMUNICATION DISORDER; CONFERENCE PAPER; DEVELOPMENTAL DISORDER; DRUG EFFICACY; EDUCATION; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PROGNOSIS; PSYCHIATRIC DIAGNOSIS; SEDATION; SIDE EFFECT; SOCIAL DISABILITY; SPEECH REHABILITATION; SPEECH THERAPY; STEREOTYPY;

EID: 0037448402     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3602.2002211     Document Type: Conference Paper

References (91)

1. Kanner L. Autistic disturbances of affective contact. Nerv Child 1943; 2: 217-50.
2. Kanner L. Follow-up study of eleven autistic children originally reported in 1943. J Autism Dev Disord 1971; 1: 119-45.
3. Cohen DJ, Volkmar F, Anderson G, Klin A. Integrating biological and behavioral perspectives in the study and care of autistic. In Cohen D, Donellan A, eds. Handbook of autism and developmental disorders. Maryland: VH Winston & Sons; 1987.
4. Damasio AR, Maurer RG. A neurological model for childhood autism. Arch Neurol 1978; 35: 777-86.
5. DeMyer M, Hingtgen L, et al. Infantile autism reviewed: a decade of research. Schizo Bull 1981; 7: 388-451.
6. Gillberg C. Infantile autism and other childhood psychoses in a Swedish urban region. J Child Psychol Psychiatry 1984; 25: 35-43.
7. Gillberg C. The neurobiology of infantile autism. J Child Psychol Psychiatry 1988; 29: 257-66.
8. Golden G. Neurological functioning. In Cohen D, Donellan A, eds. Handbook of autism and pervasive developmental disorders. New York: John Wiley & Sons; 1987. p. 677-96.
9. Provence S, Dahl KE. Disorders of atypical development: diagnostic issues raised by a spectrum disorder. In Cohen D, Donellan A, eds. Handbook of autism and pervasive developmental disorders. New York: John Wiley; 1987. p. 677-96.
10. Rapin I. Searching for the cause of autism: a neurologic perspective. In Cohen D, Donellan A, eds. Handbook of autism and pervasive developmental disorders. New York: John Wiley; 1987. p. 710-7.
11. Ritvo ER, Jorde LB, Mason-Brothers A, et al. The UCLA-University of Utah epidemiologic survey of autism: recurrence risk estimates and genetic counseling. Am J Psychiatry 1989; 146: 1032-6.
12. Ritvo ER, Jorde LB, Mason-Brothers A, et al. The UCLA-University of Utah epidemiologic survey of autism: prevalence. Am J Psychiatry 1989; 146: 194-9.
13. Rutter M, Schopler E. Classification of pervasive developmental disorders: some concepts and practical considerations. J Autism Dev Disord 1992; 22: 459-82.
14. Schopler E, Mesibov G. Autism in Adolescents and Adults. New York: Plenum Press; 1983.
15. Schreibman L. Diagnostic features of autism. J Child Neurol 1988; 3 (Suppl): S57-64.
16. Spitzer R, Siegel B. The DSM-III-R field trial of pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 1990; 29: 855-62.
17. Volkmar F, Cohen DJ. Neurobiologic aspects of autism. N Engl J Med 1988; 383: 1390-2.
18. Zahner GE, Pauls DL. Epidemiological surveys of infantile autism. In Cohen D, Donellan A, eds. Handbook of autism and pervasive developmental disorders. New York: John Wiley; 1987. p. 199-207.
19. Sugiyama T, Abe T. The prevalence of autism in Nagoya, Japan: a population study. J Autism Dev Disord 1989; 19: 87-96.
20. Percy A, Gillberg C, et al. Rett syndrome and the autistic disorders. Neurol Clin 1990; 8: 659-76.
21. Allen DA. Autistic spectrum disorders: clinical presentation in preschool children. J Child Neurol 1988; 3 (Suppl): S48-56.
22. Minshew NJ, Payton JB. New perspectives in autism. Part I: The clinical spectrum of autism. Curr Probl Pediatr 1988; 18: 561-610.
23. Minshew NJ, Payton JB. New perspectives in autism. Part II: The differential diagnosis and neurobiology of autism. Curr Probl Pediatr 1988; 18: 613-94.
24. Rapin I. Disorders of higher cerebral function in preschool children. Part I. AJDC 1988; 142: 1119-24.
25. Rapin I. Disorders of higher cerebral function in preschool children. Part II. AJDC 1988; 142: 1178-82.
26. Tuchman R, Rapin I, Shinnar S. Autistic and dysphasic children: I Clinical characteristics. Pediatrics 1991; 88: 1211-8.
27. Schopler E. Convergence of learning disability, higher level autism and Asperger's syndrome. J Autism Dev Disord 1985; 15: 359-60.
28. Tanguay P. Infantile Autism and social communication spectrum disorder. J Am Acad Child Adolesc Psychiatry 1990; 29: 854.
29. Wing L, Attwood A. Syndromes of autism and atypical development. In Cohen D, Donellan A, eds. Handbook of autism and pervasive developmental disorders. New York: John Wiley & Sons; 1987. p. 199-207.
30. DSM-IV. Pervasive developmental disorders. Diagnostic and Statistical Manual of Mental Disorders. 4 ed. Washington, DC: American Psychiatric Association; 1994. p. 65-78.
31. Rapin I. Autistic children: diagnosis and clinical features. Pediatrics 1991; 87: 751-60.
32. Gillberg C, Coleman M. Prevalence of autism and autistic-like conditions. The Biology of the autistic syndromes. New York: MacKeith Press; 1992. p. 85-95.
33. Kurtzke J. Neuroepidemiology. In Bradley W, Daroff R, Fenichel G, Marsden C, eds. Neurology in clinical practice. Stoneham: Butterworth-Heinemann; 1991. p. 545-60.
34. Cohen DJ, Volkmar F, et al. Integrating biological and behavioral perspectives in the study and care of autistic individuals: the future. Isr J Psychiatry Relat Sci 1993; 30: 15-32.
35. Rutter M, Schopler E. Classification of pervasive developmental disorders: some concepts and practical considerations. J Autism Dev Disord 1992; 22: 459-82.
36. Percy A. Genetics of Rett syndrome: properties of the newly discovered gene and pathobiology of the disorder. Curr Opin Pediatr 2000; 12: 589-95.
37. Gillberg C, Coleman M. Theoretical considerations: CNS mechanisms underlying the autistic syndromes. The biology of the autistic syndromes. New York: MacKeith Press; 1992. p. 283-95.
38. Schopler E, Reichler R, Renner B. Childhood Autism Rating Scale (CARS). Los Angeles: Western Psychological Services; 1986.
39. Volkmar FR, Carter A, Sparrow SS, Cicchetti DV. Quantifying social development in autism. J Am Acad Child Adolesc Psychiatry 1993; 32: 627-32.
40. LeCouteur A, Rutter M, Lord C, Rios P, Robertson S, Holdgrafer M, et al. Autism Diagnostic Interview: a standardized investigator-based instrument. J Autism Dev Disord 1989; 19: 363-87.
41. Lord C. Methods and measures of behavior in the diagnosis of autism and related disorders. Psychiatr Clin N Am 1991; 14: 69-80.
42. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994; 24: 659-85.
43. Lord C, Pickles A, McLennan J, Rutter M, Bregman J, Folstein S, et al. Diagnosing autism: analyses of data from the Autism Diagnostic Interview. J Autism Dev Disord 1997; 27: 501-17.
44. Robertson JM, Tanguay PE, L'Ecuyer S, Sims A, Waltrip C. Domains of social communication handicap in autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 738-45.
45. Mesibov G. Current perspectives and issues in autism and adolescence. In Schopler E, Mesibov G, eds. Autism in Adolescents and Adults. New York: Plenum Press; 1983. p. 37-53.
46. Damasio A, Maurer R. A neurological model for childhood autism. Arch Neurol 1978; 35: 777-86.
47. Rumsey J, Rapoport J, Sceery W. Autistic children as adults: Psychiatric, social and behavioral outcomes. J Am Acad Child Adolesc Psychiatry 1985; 24: 465-73.
48. Jones V, Prior M. Motor imitation abilities and neurological signs in autistic children. J Autism Dev Disord 1985; 15: 37-46.
49. Vilensky J, Damasio A, Maurer R. Gait disturbances in patients with autistic behavior. Arch Neurol 1981; 38: 646-9.
50. Hallet M, Lebiedowska M, Thomas S, Stanhope S, Denckla M, Rumsey J. Locomotion of autistic adults. Arch Neurol 1993; 50: 1304-8.
51. Meiselas K, Spencer E, Oberfield R. Differentiation of stereotypies from neuroleptic-related dyskinesias in autistic children. J Clin Psychopharmacol 1989; 9: 207-9.
52. Tuchman R, Rapin I, et al. Autistic and dysphasic children. II: Epilepsy. Pediatrics 1991; 88: 1219-25 [errata in Pediatrics 1992; 90: 264].
53. Volknar F, Nelson D. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry 1990; 29: 127-9.
54. Gillberg C. Outcome in autism and autistic-like conditions. J Am Acad Child Adolesc Psychiatry 1991; 30: 375-82.
55. Deykin E, MacMahon B. The incidence of seizures among children with autistic symptoms. Am J Psychiatry 1979; 136: 1310-2.
56. Ballaban-Gil K, Rapin I, Tuchman R, Freeman K, Shinnar S. The risk of seizures in autistic individuals: Occurrence of a secondary peak in adolescence. Epilepsia 1991; 32 (Suppl 3): S84.
57. Goulding P, Méndez S, Gibbons V, Hansen D, Kotagal S. The relationship between alterations in sleep architecture and daytime neuropsychological functions. Ann Neurol 1993; 34: 504.
58. Anderson L, Campbell M, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141: 1195-202.
59. Anderson L, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989; 19: 227.
60. Findling R, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997; 33: 155.
61. McDougle C, Holmes J, Bronson M, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 1997; 36: 685.
62. Gilman J, Tuchman R. Autism and associated behavioral disorders: pharmacotherapeutic intervention. Ann Pharmacother 1995; 29: 47-56.
63. Campbell M, Anderson L, et al. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol Bull 1990; 26: 130-5.
64. Center for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations. JAMA 1997; 278: 1729.
65. Brasic J, Barnett J, Sheitman B, et al. Adverse effects of clomipramine (letter). J Am Acad Child Adolesc Psychiatry 1997; 36: II65.
66. Gordon C, State R, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50: 441-7.
67. McCormick L. Treatment with buspirone in a patient with autism. Arch Fam Med 1997; 6: 368.
68. Pfeiffer S, Norton J, Nelson L, et al. Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. J Autism Dev Disord 1995; 25: 481.
69. Findling R, Maxwell K, Scotese-Wojtila L, et al. High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. J Autism Dev Disord 1997; 27: 467.
70. Horvath K, Stefanatos G, et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Physiol 1998; 9: 9-15.
71. Sandler A, Sutton K, DeWeese J, et al. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder (see comments). N Engl J Med 1999; 341: 1801-6.
72. Owley T, Steele E, Corselo C, et al. A double-blind, placebo-controlled trial of secretin for the treatment of autistic disorder. Med Gen Med 1999; E2.
73. Chez M, Buchanan C, Bagan B, et al. Secretin and autism: a two-part clinical investigation. J Autism Dev Disord 2000; 30: 87-94.
74. Dunn-Geier J, Ho H, Auersperg E, et al. Effect of secretin on children with autism: a randomized controlled trial. Dev Med Child Neurol 2000; 42: 796-802.
75. Roberts W, Weaver L, Brian J, et al. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics 2001; 107: 71.
76. Owley T, William M, Cook E, et al. Multisite, double-blind, placebocontrolled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry 2001; 40: 1293-9.
77. Buitelaar J, van Engeland H, et al. Deficits in social behavior in autism and their modification by a synthetic adrenocorticotrophic hormone (4-9) analog. Experientia 1992; 48: 391-4.
78. Nass R, Petrucha D. Acquired aphasia with convulsive disorder: A pervasive developmental disorder variant. J Child Neurol 1990; 5: 327-8.
79. Plioplys A. Autism: electroencephalogram abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med 1994; 148: 220-2.
80. Stefanatos G, Grover W, et al. Case study: corticosteroid treatment of language regression in pervasive developmental disorder (see comments). J Am Acad Child Adolesc Psychiatry 1995; 34: 1107-11.
81. Nass R, Gross A, Wisoff J, Devinsky O. Outcome of multiple subpial transections for autistic epileptiform regression. Pediatr Neurol 1999; 21: 464-70.
82. Neville B, Harkness W, et al. Surgical treatment of severe autistic regression in childhood epilepsy. Pediatr Neurol 1997; 16: 137-40.
83. Szabo C, Wyllie E, et al. Epilepsy surgery in children with pervasive developmental disorder. Pediatr Neurol 1999; 20: 349-53.
84. Lewine J, Andrews R, et al. Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders (see comments). Pediatrics 1999; 104: 405-18.
85. Tuchman R, Gilman J. Pharmacotherapy of pervasive developmental disorders. Int Pediatr 1993; 8: 211-8.
86. Lotter V. Follow-up Studies. In Rutter M, Schopler E, eds. Autism. A Reappraisal of Concepts and Treatment. New York: Plenum Press; 1978. p. 475-95.
87. Gillberg C, Steffenburg S. Outcome and prognostic factors in infantile autism and similar conditions: a population-based study of 46 cases followed through puberty. J Autism Dev Disord 1987; 17: 273-87.
88. Wing L. Autistic adults. In Gilberg C, ed. Diagnosis and treatment of autism. New York: Plenum Press; 1989. p. 419-32.
89. Paul R. Natural history. In Cohen D, Donellan A, eds. Handbook of autism and pervasive developmental disorders. New York: John Wiley; 1987. p. 121-30.
90. Kobayashi R, Murata T, et al. A follow-up study of 201 children with autism in Kyushu and Yamaguchi areas, Japan. J Autism Dev Disord 1992; 22: 395-411.
91. McEachin J, Smith T, et al. Long-term outcome for children with autism who received early intensive behavioral treatment. Am J Ment Retard 1993; 97: 359-72; discussion, 373-91.